Top 10 Food Allergy Management Questions

Target Audience

The educational design of this activity addresses the needs of allergy/clinical immunology and pediatric clinicians (MDs, NPs, and PAs) who are involved in managing adult and pediatric patients with food allergies.

Program Overview

For the millions of children and adults living with food allergies, the risk of accidental exposure and potential life-threatening reactions are a daily reality. The physical, psychosocial, and financial burdens are significant for patients with food allergies and their caregivers. Biologics, such as omalizumab, and peanut oral immunotherapy are now being incorporated into the food allergy management paradigm, offering the potential to reduce risks of allergen exposure and improve patient quality of life. In this activity, Dr Edwin Kim answers commonly asked questions about the diagnosis and management of immunoglobulin E (IgE)-mediated food allergies, including the identification of IgE-mediated allergy, current recommendations on early introduction of foods to prevent food allergies, prescribing parameters for new therapeutic modalities, and disparities in patient burdens associated with food allergies.

Educational Objectives

After completing this activity, the participant should be better able to:

1. Discuss the biopsychosocial burdens and historical management challenges associated with food allergy
2. Describe the clinical profiles and evidence for new strategies for the management of IgE-mediated food allergy
3. Individualize management regimens for adult and pediatric patients with food allergy based on new evidence and shared decision-making

Physician Accreditation Statement

Integritas Communications is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physician Credit Designation

Integritas designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Integritas Contact Information

For more information about the approval of this program, please contact Integritas at info@exchangecme.com.

Instructions to Receive Credit

In order to receive credit for this activity, the participant must complete the preactivity questionnaire, score 75% or better on the posttest, and complete the program evaluation.

Fee Information & Refund/Cancellation Policy

There is no fee for this educational activity.

Disclosures of Conflicts of Interest

Integritas adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Integritas are required to disclose all financial relationships with any ineligible company within the past 24 months to Integritas.  All financial relationships reported are identified as relevant and mitigated by Integritas in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Integritas to assure objectivity and that the activity is free of commercial bias. 

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:

Edwin Kim, MD: Consulting Fees: Allakos Inc., ALK-Abelló A/S, Cellergy Pharma, DBV Technologies, Genentech, GrowHappy, Hanimune Therapeutics, Novartis, Phylaxis BioScience, Revolo Biotherapeutics, Ukko

The planners and managers have no relevant financial relationships with ineligible companies.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Integritas does not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.